Social Cognition Assessment and Rehabilitation for Families living with Brain Tumour (SCARF-BT): a feasibility study

Cambridge University Hospitals NHS Foundation Trust0 个研究点目标入组 60 人开始时间: 2021年4月30日最近更新: 2022年9月19日

适应症

试验速览

暂无简介。

•1. Patients pre-screened as part of the CogENT and SIND studies, scoring 11 or less on the emotional recognition test within the OCS-Bridge screening tool done pre-operatively (consistent with having a deficit pre-operatively)
•2. Signed Informed Consent to SCARF-BT study
•3. Aged 18 years and older
•4. Imaging evidence of a high-grade glioma as assessed by a neuro-oncology MDT
•5. MDT and treating clinician recommend either biopsy or debulking of the tumour; 6. Patients scoring 11 or less on the emotional recognition test within the OCS-Bridge screening tool done post-operatively (consistent with having a deficit post-operatively)
•7. Patients with WHO Performance status 0-2
•8. Patients suitable for oncological intervention (involving radiotherapy/ chemotherapy/ combining radiotherapy and chemotherapy)
•9. For Qualitative Study only: speaks fluent English as the use of interpreters can alter patients exact words
•10. For Qualitative Study only: willing to participate in the interviews and/or focus groups
•1. Written informed consent
•2. Family member/someone they care for with Brain Tumour who is participating in this study
•3. Able and willing to complete the caregiver Quality of Life questionnaire
•4. For Qualitative Study only: speaks fluent English as the use of interpreters can alter patients exact words
•5. For Qualitative Study only: willing to participate in interviews and/or focus groups

•1. Patients unable to give written consent or who lack capacity to consent
•2. Patients for palliative/best supportive care only, following surgery
•3. Pre-morbid developmental or acquired/traumatic neurologic disorder (e.g. autism, stroke, severe head injury or dementia/cognitive impairment)
•4. Pre-morbid major psychiatric disorder (e.g., schizophrenia)
•Impaired vision and/or hearing that would interfere with task participation (determined by interacting with participant on screening and medical history)
•5. Patients have impairment of facial recognition (i.e. prosopagnosia) using the OCS-Bridge screening tool score of >5 on immediate assessment
•6. Impaired facial recognition (i.e. prosopagnosia) using a separate test from the OCS-Bridge screening tool, where a score of =5 on immediate assessment of neutral face recognition would suggest a deficit requiring exclusion

发起方